The renowned immunology expert Curran is an Associate Professor at The University of Texas MD Anderson Cancer Center and cofounder of the Oncology Research for Biologics and Immunotherapy Translation (ORBIT) platform, which coordinates the development and production of clinical immunotherapeutic antibodies. He received a Ph.D. in Immunology from Stanford University, where he was awarded the McDevitt Prize for the best graduate thesis in his year and was the first recipient of the prestigious American Cancer Society Levy Fellowship to fund his post-doctoral studies in the lab of Dr James P. Allison at Memorial Sloan-Kettering Cancer Center.

"I am excited to help ImmunOs advance their first-in-class therapeutics, including the lead oncology program, IOS-1002, which targets multiple myeloid checkpoints," said Dr Curran. "This is a truly novel immunotherapy approach based on multi-specific HLA proteins, which have the potential to modulate the entire immune system and have led to promising treatment options for both cancer and autoimmune diseases."

In addition to Dr Curran, Taha Merghoub, PhD, Ulf Petrausch, MD, and Paul Bowness, MD, PhD, currently serve as Scientific Advisors to ImmunOs. The Company is located in Schlieren (CH) and Gaithersburg (MD, USA).